equity-research

ina

INA: Lifestyle Communities Developer - Demographics Can't Save Overpriced Dreams

Updated 8 Oct 2025

HOLD rating with $3.60 fair value vs $5.96 current price. Strong demographics offset by execution risks and regulatory headwinds.

View note

imr

IMR: MRI-Guided Pioneer - Monopoly's Mirage at Extreme Multiples

Updated 8 Oct 2025

Fair value $0.30 vs current $1.37 implies 78% downside risk. Monopolistic MRI-compatible cardiac ablation technology with FDA approval catalyst, but extreme 195x revenue valuation creates unfavourable risk-reward profile.

View note

imd

IMD: Mining Tech Pioneer - Digital Dreams Meet Drilling Reality

Updated 8 Oct 2025

Mining technology leader trading at 44% premium to $2.36 fair value. Strong 29.3% EBITDA margins, 490+ patents, but execution risks from three simultaneous acquisitions amid uncertain exploration recovery.

View note

igl

IGL: Print Giant - Transformation's the New Black

Updated 8 Oct 2025

IVE Group trades at $2.99 vs fair value $8.19, offering 174% upside through portfolio transformation from print to packaging/logistics. Market leader with strong execution track record.

View note

idx

IDX: Diagnostic Imaging Giant - Leveraged to the Hilt, Priced for Perfection

Updated 8 Oct 2025

Australia's #2 diagnostic imaging provider trading at 129% premium to $1.16 fair value. High leverage, workforce constraints, and technology disruption create asymmetric downside risk.

View note

ibx

IBX: Biotech Bubble - MagSense® Makes No Sense at These Levels

Updated 8 Oct 2025

Clinical-stage biotechnology company trading at $1.62 vs fair value $0.13, facing 65% Phase 2 failure probability with extreme dilution risk ahead.

View note

hvn

HVN: Retail Giant - Peak Margins, Property Peaks, and Painful Reality Checks

Updated 8 Oct 2025

Harvey Norman trades at $7.29 vs $3.13 fair value (57% overvalued) with unsustainable margins and property cycle risks creating compelling value opportunity

View note

hdn

HDN: Daily Needs REIT - Pipeline's Running Dry, Premium's Running High

Updated 8 Oct 2025

Trading at $1.00 vs fair value $0.88. Business quality 5.9/10, EBITDA margins compressing 49.9% to 44.7%. Development pipeline finite, competitive moat narrowing 4-6 years.

View note

gwa

GWA: Water Solutions Giant - Plumbing the Depths of Value

Updated 8 Oct 2025

HOLD rating with $2.26 fair value vs $2.65 current price. Strong 5.85% dividend yield offset by customer concentration risks and margin compression pressures.

View note

gqg

GQG: Global Asset Manager - Defensive Genius or Margin Mirage?

Updated 8 Oct 2025

HOLD rating with $1.47 fair value vs $1.757 current price. Exceptional 76% EBITDA margins offset by defensive positioning headwinds and succession risk.

View note

gpt

GPT: Diversified REIT Giant - Caught Between Specialists and Structural Decline

Updated 8 Oct 2025

HOLD rating with $4.75 fair value vs $5.27 current price. 98.5% occupancy but office headwinds and 7.2x leverage create challenging outlook.

View note

gng

GNG: Engineering Services Specialist - Peak Performance, Peak Problems

Updated 8 Oct 2025

HOLD rating with $3.61 fair value vs $4.27 current price. Exceptional ROIC 71.6% offset by cyclical peak timing concerns and inevitable margin compression.

View note